Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone ...
A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...
Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...
Pliant Therapeutics (PLRX) announced that, per the charter of the trial’s independent Data Safety Monitoring Board, DSMB, the Company has ...
The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...
Clinical Trials Arena on MSN3d
Boehringer seeks approval of lung disease drug after second Phase III successBoehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
The AI model works by examining each video frame to find important features of the lungs and assesses the order of the video ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback